Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition

Leukemia

Volumn 28, Issue 8, 2014, Pages 1606-1616

  Sapienza, M R ^a   Fuligni, F ^a   Agostinelli, C ^a   Tripodo, C ^b   Righi, S ^a   Laginestra, M A ^a   Pileri, A ^c   Mancini, M ^a   Rossi, M ^a   Ricci, F ^a   Gazzola, A ^a   Melle, F ^a   Mannu, C ^a   Ulbar, F ^a   Arpinati, M ^a   Paulli, M ^d   Maeda, T ^e   Gibellini, D ^a   Pagano, L ^f   Pimpinelli, N ^c   Santucci, M ^c   Cerroni, L ^g   Croce, C M ^h   Facchetti, F ⁱ   Piccaluga, P P ^a   Pileri, S A ^a   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^f CATHOLIC UNIVERSITY   (Italy)

^g MEDICAL UNIVERSITY OF GRAZ   (Austria)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BIOINFORMATICS; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EX VIVO STUDY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VALIDATION PROCESS;

CELL CYCLE; DENDRITIC CELLS; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOID, ACUTE; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84905519085     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.64     Document Type: Article

References (56)

1. Facchetti F JD, Petrella T. Blastic plasmacytoid dendritic cell neoplasms. In WHO Classification of Tumors of Haematopoietic and Lymphoid TissuesSwerdlow SH, Campo E, Harris NL et al. (eds) IARC: Lyon, France, 2008, pp 145-147.
2. Assaf C, Gellrich S, Whittaker S, Robson A, Cerroni L, Massone C et al. CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer. J Clin Pathol 2007; 60: 981-989.
3. Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 1997; 185: 1101-1111.
4. Cella M, Facchetti F, Lanzavecchia A, Colonna M. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol 2000; 1: 305-310.
5. Soumelis V, Liu YJ. From plasmacytoid to dendritic cell: morphological and functional switches during plasmacytoid pre-dendritic cell differentiation. Eur J Immunol 2006; 36: 2286-2292.
6. Feuillard J, Jacob MC, Valensi F, Maynadie M, Gressin R, Chaperot L et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 2002; 99: 1556-1563.
7. Garnache-Ottou F, Feuillard J, Saas P. Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity? Br J Haematol 2007; 136: 539-548.
8. Facchetti F, Ungari M, Marocolo D, Lonardi S, Vermi W. Blastic plasmacytoid dendritic cell neoplasm. Hematol Meet Rep 2009; 3: 1-3.
9. Bendriss-Vermare N, Chaperot L, Peoc'h M, Vanbervliet B, Jacob MC, Briere F et al. In situ leukemic plasmacytoid dendritic cells pattern of chemokine receptors expression and in vitro migratory response. Leukemia 2004; 18: 1491-1498.
10. Petrella T, Bagot M, Willemze R, Beylot-Barry M, Vergier B, Delaunay M et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol 2005; 123: 662-675.
11. Chen J, Zhou J, Qin D, Xu S, Yan X. Blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol 2011; 29: e27-e29.
12. Tsagarakis NJ, Kentrou NA, Papadimitriou KA, Pagoni M, Kokkini G, Papadaki H et al. Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. Leuk Res 2010; 34: 438-446.
13. Jegalian AG, Facchetti F, Jaffe ES. Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv Anat Pathol 2009; 16: 392-404.
14. Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica 2013; 98: 239-246.
15. Pileri A, Delfino C, Grandi V, Agostinelli C, Pileri SA, Pimpinelli N. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the cutaneous sanctuary. G Ital Dermatol Venereol 2012; 147: 603-608.
16. Piccaluga PP, Paolini S, Sapienza MR, Pileri SA. Blastic plasmacytoid dendritic cell neoplasm: is it time to redefine the standard of care? Expert Rev Hematol 2012; 5: 353-355.
17. Petrella T, Dalac S, Maynadie M, Mugneret F, Thomine E, Courville P et al. CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Francais d'Etude des Lymphomes Cutanes (GFELC). Am J Surg Pathol 1999; 23: 137-146.
18. Leroux D, Mugneret F, Callanan M, Radford-Weiss I, Dastugue N, Feuillard J et al. CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Francais de Cytogenetique Hematologique. Blood 2002; 99: 4154-4159.
19. Reichard KK, Burks EJ, Foucar MK, Wilson CS, Viswanatha DS, Hozier JC et al. CD4(+) CD56(+) lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol 2005; 29: 1274-1283.
20. Dijkman R, van Doorn R, Szuhai K, Willemze R, Vermeer MH, Tensen CP. Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood 2007; 109: 1720-1727.
21. Jardin F, Callanan M, Penther D, Ruminy P, Troussard X, Kerckaert JP et al. Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease. Leukemia 2009; 23: 698-707.
22. Wiesner T, Obenauf AC, Cota C, Fried I, Speicher MR, Cerroni L. Alterations of the cell-cycle inhibitors p27(KIP1) and p16(INK4a) are frequent in blastic plasmacytoid dendritic cell neoplasms. J Invest Dermatol 2009; 130: 1152-1157.
23. Lucioni M, Novara F, Fiandrino G, Riboni R, Fanoni D, Arra M et al. Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. Blood 2011; 118: 4591-4594.
24. Biddolph SC, Gatter K. Lymphocytes: a practical approach. In Rowland-Jones SL, McMichael AJ (eds). Immunohistochemistry of Lymphoid Organs. Oxford UOUP, 2000, pp 27-54.
25. Agostinelli C, Paterson JC, Gupta R, Righi S, Sandri F, Piccaluga PP et al. Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody. Histopathology 2012; 61: 33-46.
26. Maeda T, Murata K, Fukushima T, Sugahara K, Tsuruda K, Anami M et al. A novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma. Int J Hematol 2005; 81: 148-154.
27. Ng AP, Lade S, Rutherford T, McCormack C, Prince HM, Westerman DA. Primary cutaneous CD4+/CD56+ hematodermic neoplasm (blastic NK-cell lymphoma): a report of five cases. Haematologica 2006; 91: 143-144.
28. Rathinam C, Sauer M, Ghosh A, Rudolph C, Hegazy A, Schlegelberger B et al. Generation and characterization of a novel hematopoietic progenitor cell line with DC differentiation potential. Leukemia 2006; 20: 870-876.
29. Panoskaltsis N. Dendritic cells in MDS and AML - cause, effect or solution to the immune pathogenesis of disease? Leukemia 2005; 19: 354-357.
30. Sathe P, Vremec D, Wu L, Corcoran L, Shortman K. Convergent differentiation: myeloid and lymphoid pathways to murine plasmacytoid dendritic cells. Blood 2013; 121: 11-19.
31. Ishikawa F, Niiro H, Iino T, Yoshida S, Saito N, Onohara S et al. The developmental program of human dendritic cells is operated independently of conventional myeloid and lymphoid pathways. Blood 2007; 110: 3591-3660.
32. Yang GX, Lian ZX, Kikuchi K, Moritoki Y, Ansari AA, Liu YJ et al. Plasmacytoid dendritic cells of different origins have distinct characteristics and function: studies of lymphoid progenitors versus myeloid progenitors. J Immunol 2005; 175: 7281-7287.
33. Sprenger CC, Drivdahl RH, Woodke LB, Eyman D, Reed MJ, Carter WG et al. Senescence-induced alterations of laminin chain expression modulate tumorigenicity of prostate cancer cells. Neoplasia 2008; 10: 1350-1361.
34. Hung WY, Huang KH, Wu CW, Chi CW, Kao HL, Li AF et al. Mitochondrial dysfunction promotes cell migration via reactive oxygen species-enhanced beta5-integrin expression in human gastric cancer SC-M1 cells. Biochim Biophys Acta 2012; 1820: 1102-1110.
35. Yamatoji M, Kasamatsu A, Kouzu Y, Koike H, Sakamoto Y, Ogawara K et al. Dermatopontin: a potential predictor for metastasis of human oral cancer. Int J Cancer 2012; 130: 2903-2911.
36. Tamamura R, Nagatsuka H, Siar CH, Katase N, Naito I, Sado Y et al. Comparative analysis of basal lamina type IV collagen alpha chains, matrix metalloproteinases-2 and -9 expressions in oral dysplasia and invasive carcinoma. Acta Histochem 2013; 115: 113-119.
37. Hatfield KJ, Hovland R, Oyan AM, Kalland KH, Ryningen A, Gjertsen BT et al. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia 2007; 22: 287-293.
38. Van Driessche A, Gao L, Stauss HJ, Ponsaerts P, Van Bockstaele DR, Berneman ZN et al. Antigen-specific cellular immunotherapy of leukemia. Leukemia 2005; 19: 1863-1871.
39. Galteland E, Sivertsen EA, Svendsrud DH, Smedshammer L, Kresse SH, Meza-Zepeda LA et al. Translocation t(14; 18) and gain of chromosome 18//BCL2: effects on BCL2 expression and apoptosis in B-cell non-Hodgkin's lymphomas. Leukemia 2005; 19: 2313-2323.
40. Wang M, Sun L, Qian J, Han X, Zhang L, Lin P et al. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia 2009; 23: 1320-1328.
41. Reed JC, Zha H, Aime-Sempe C, Takayama S, Wang HG. Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death. Adv Exp Med Biol 1996; 406: 99-112.
42. Willis S, Day CL, Hinds MG, Huang DC. The Bcl-2-regulated apoptotic pathway. J Cell Sci 2003; 116: 4053-4056.
43. Turco MC, Romano MF, Petrella A, Bisogni R, Tassone P, Venuta S. NF-[kappa]B//Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia 2003; 18: 11-17.
44. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-436.
45. Sarkar FH, Li Y, Wang Z, Kong D. NF-kappaB signaling pathway and its therapeutic implications in human diseases. Int Rev Immunol 2008; 27: 293-319.
46. Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009; 23: 2222-2232.
47. Satou Y, Nosaka K, Koya Y, Yasunaga Ji, Toyokuni S, Matsuoka M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 2004; 18: 1357-1363.
48. Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 2009; 23: 1964-1979.
49. Hirai M, Kadowaki N, Kitawaki T, Fujita H, Takaori-Kondo A, Fukui R et al. Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis. Blood 2011; 117: 500-509.
50. Hartmann S, Gesk S, Scholtysik R, Kreuz M, Bug S, Vater I et al. High resolution SNP array genomic profiling of peripheral T cell lymphomas, not otherwise specified, identifies a subgroup with chromosomal aberrations affecting the REL locus. Br J Haematol 2010; 148: 402-412.
51. Martinez-Delgado B, Cuadros M, Honrado E, Ruiz de la Parte A, Roncador G, Alves J et al. Differential expression of NF-[kappa]B pathway genes among peripheral T-cell lymphomas. Leukemia 2005; 19: 2254-2263.
52. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459: 717-721.
53. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12: 115-130.
54. Yamamoto M, Ito T, Shimizu T, Ishida T, Semba K, Watanabe S et al. Epigenetic alteration of the NF-kappaB-inducing kinase (NIK) gene is involved in enhanced NIK expression in basal-like breast cancer. Cancer Sci 2010; 101: 2391-2397.
55. Garg A, Aggarwal BB. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 2002; 16: 1053-1068.
56. Piccaluga PP, Fuligni F, De Leo A, Bertuzzi C, Rossi M, Bacci F et al. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase iii diagnostic accuracy study. J Clin Oncol 2013; 31: 3019-3025.